Johnson & Johnson (JNJ)
153.58
+0.00 (0.00%)
NYSE · Last Trade: May 30th, 6:37 AM EDT

Via The Motley Fool · May 29, 2025

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.
Via Investor's Business Daily · May 29, 2025
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via Benzinga · May 27, 2025
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.
Via Benzinga · May 27, 2025
Via The Motley Fool · May 27, 2025
Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.
Via Chartmill · May 26, 2025
Via The Motley Fool · May 25, 2025
Via The Motley Fool · May 24, 2025
Via The Motley Fool · May 23, 2025
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider
Via MarketBeat · May 22, 2025
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.
Via The Motley Fool · May 18, 2025
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.
Via Benzinga · May 16, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Via Benzinga · May 15, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
Via Benzinga · May 14, 2025
President Trump unveils a $600 billion Saudi investment package into the U.S., with major deals in tech, defense, energy, and healthcare.
Via Benzinga · May 13, 2025